Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MAGI3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MAGI3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MAGI3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MAGI3_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/MAGI3_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAGI3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MAGI3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAGI3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAGI3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MAGI3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAGI3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004632821 | Lung | MIAC | regulation of JNK cascade | 15/967 | 133/18723 | 3.64e-03 | 4.60e-02 | 15 |
GO:003109816 | Oral cavity | OSCC | stress-activated protein kinase signaling cascade | 141/7305 | 247/18723 | 5.74e-09 | 1.25e-07 | 141 |
GO:005140316 | Oral cavity | OSCC | stress-activated MAPK cascade | 134/7305 | 239/18723 | 6.02e-08 | 1.09e-06 | 134 |
GO:007030210 | Oral cavity | OSCC | regulation of stress-activated protein kinase signaling cascade | 111/7305 | 195/18723 | 2.82e-07 | 4.34e-06 | 111 |
GO:000675318 | Oral cavity | OSCC | nucleoside phosphate metabolic process | 247/7305 | 497/18723 | 6.28e-07 | 8.96e-06 | 247 |
GO:000911719 | Oral cavity | OSCC | nucleotide metabolic process | 243/7305 | 489/18723 | 7.80e-07 | 1.09e-05 | 243 |
GO:003287210 | Oral cavity | OSCC | regulation of stress-activated MAPK cascade | 108/7305 | 192/18723 | 8.97e-07 | 1.22e-05 | 108 |
GO:00091233 | Oral cavity | OSCC | nucleoside monophosphate metabolic process | 50/7305 | 76/18723 | 2.04e-06 | 2.62e-05 | 50 |
GO:001969319 | Oral cavity | OSCC | ribose phosphate metabolic process | 199/7305 | 396/18723 | 2.97e-06 | 3.64e-05 | 199 |
GO:000925919 | Oral cavity | OSCC | ribonucleotide metabolic process | 189/7305 | 385/18723 | 3.18e-05 | 2.87e-04 | 189 |
GO:00091614 | Oral cavity | OSCC | ribonucleoside monophosphate metabolic process | 38/7305 | 58/18723 | 3.91e-05 | 3.43e-04 | 38 |
GO:000913217 | Oral cavity | OSCC | nucleoside diphosphate metabolic process | 70/7305 | 124/18723 | 6.03e-05 | 4.95e-04 | 70 |
GO:00072548 | Oral cavity | OSCC | JNK cascade | 90/7305 | 167/18723 | 6.49e-05 | 5.26e-04 | 90 |
GO:00463288 | Oral cavity | OSCC | regulation of JNK cascade | 74/7305 | 133/18723 | 7.22e-05 | 5.69e-04 | 74 |
GO:00091268 | Oral cavity | OSCC | purine nucleoside monophosphate metabolic process | 30/7305 | 44/18723 | 8.41e-05 | 6.44e-04 | 30 |
GO:007252120 | Oral cavity | OSCC | purine-containing compound metabolic process | 199/7305 | 416/18723 | 1.34e-04 | 9.53e-04 | 199 |
GO:000915020 | Oral cavity | OSCC | purine ribonucleotide metabolic process | 178/7305 | 368/18723 | 1.45e-04 | 1.02e-03 | 178 |
GO:000918518 | Oral cavity | OSCC | ribonucleoside diphosphate metabolic process | 60/7305 | 106/18723 | 1.78e-04 | 1.21e-03 | 60 |
GO:000913519 | Oral cavity | OSCC | purine nucleoside diphosphate metabolic process | 58/7305 | 103/18723 | 2.73e-04 | 1.73e-03 | 58 |
GO:000917919 | Oral cavity | OSCC | purine ribonucleoside diphosphate metabolic process | 58/7305 | 103/18723 | 2.73e-04 | 1.73e-03 | 58 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAGI3 | SNV | Missense_Mutation | novel | c.77N>T | p.Pro26Leu | p.P26L | Q5TCQ9 | protein_coding | tolerated(0.34) | benign(0.088) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
MAGI3 | SNV | Missense_Mutation | | c.2056N>A | p.Gln686Lys | p.Q686K | Q5TCQ9 | protein_coding | deleterious(0.04) | possibly_damaging(0.493) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
MAGI3 | SNV | Missense_Mutation | novel | c.1031G>T | p.Gly344Val | p.G344V | Q5TCQ9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5T-A9QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
MAGI3 | SNV | Missense_Mutation | | c.3715N>C | p.Ile1239Leu | p.I1239L | Q5TCQ9 | protein_coding | tolerated_low_confidence(0.65) | benign(0.001) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
MAGI3 | SNV | Missense_Mutation | | c.3508N>C | p.Lys1170Gln | p.K1170Q | Q5TCQ9 | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.59) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAGI3 | SNV | Missense_Mutation | rs573108619 | c.3941G>A | p.Arg1314Gln | p.R1314Q | Q5TCQ9 | protein_coding | tolerated_low_confidence(0.3) | benign(0.001) | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAGI3 | SNV | Missense_Mutation | novel | c.655N>G | p.Gln219Glu | p.Q219E | Q5TCQ9 | protein_coding | deleterious(0.03) | possibly_damaging(0.845) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
MAGI3 | SNV | Missense_Mutation | novel | c.1433A>C | p.Gln478Pro | p.Q478P | Q5TCQ9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A56Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
MAGI3 | SNV | Missense_Mutation | novel | c.3782G>T | p.Gly1261Val | p.G1261V | Q5TCQ9 | protein_coding | tolerated_low_confidence(0.22) | benign(0.003) | TCGA-E2-A573-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
MAGI3 | SNV | Missense_Mutation | novel | c.3708N>T | p.Leu1236Phe | p.L1236F | Q5TCQ9 | protein_coding | tolerated_low_confidence(0.44) | benign(0.157) | TCGA-E9-A22D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |